Susquehanna International Group’s LENZ Therapeutics LENZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$136K Sell
14,900
-29,700
-67% -$417K ﹤0.01% 12108
2025
Q4
$714K Buy
44,600
+26,700
+149% +$778K ﹤0.01% 7979
2025
Q3
$834K Sell
17,900
-156,600
-90% -$5.76M ﹤0.01% 7784
2025
Q2
$5.11M Buy
+174,500
New +$4.75M ﹤0.01% 3925
2023
Q3
Sell
-15,686
Closed -$285K 13161
2023
Q2
$285K Sell
15,686
-243
-2% -$4.86K ﹤0.01% 9537
2023
Q1
$273K Buy
15,929
+11,715
+278% +$189K ﹤0.01% 9925
2022
Q4
$97.9K Sell
4,214
-4,929
-54% -$114K ﹤0.01% 10982
2022
Q3
$203K Buy
9,143
+6,057
+196% +$144K ﹤0.01% 10808
2022
Q2
$59K Buy
+3,086
New +$68.8K ﹤0.01% 11877

Other funds holding LENZ

Susquehanna International Group's LENZ Position: Q1 2026 in Review

Susquehanna International Group increased its LENZ Therapeutics (LENZ) stake by 63% in Q1 2026, buying an estimated $598K and bringing the position to 110,304 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #7852.

Susquehanna International Group first reported a position in LENZ in Q4 2022 and has held it in 10 quarters since. The position peaked at $2.35M in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Susquehanna International Group held 110,304 shares of LENZ Therapeutics worth $1.01M as of Q1 2026.
  • Susquehanna International Group bought 42,582 LENZ Therapeutics shares in Q1 2026, an estimated $598K.
  • LENZ Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7852 holding.
  • Susquehanna International Group first reported a position in LENZ Therapeutics in Q4 2022 and has held it in 10 quarters since.
  • Susquehanna International Group's LENZ Therapeutics position peaked at $2.35M in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.